This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The case arose from Alexion Pharmaceuticals, Inc.’s s 2018 acquisition of Syntimmune, Inc. A recent Delaware Chancery Court opinion offers a significant example of how courts may apply complex probability analysis to determine the amount of damages in an earnout dispute.
Great Point Partners (GPP) has announced the acquisition of a majority stake in Eutecma. Eutecma, founded in 2008 and based in Germany, is a developer of temperature-controlled packaging solutions for pharmaceutical cold chain shipments. By: McGuireWoods LLP
The UK DMCC forms part of a global trend to focus merger review increasingly on vertical concerns and concerns about eliminating nascent competition, including by so-called “killer acquisitions” of firms perceived as future competitive threats. The reforms are particularly relevant to the technology and pharmaceutical.
s (Amgen) proposed acquisition of Horizon Therapeutics plc (Horizon). On May 17, 2023, the Federal Trade Commission (FTC) challenged Amgen Inc.’s The complaint is significant in three respects. By: Wilson Sonsini Goodrich & Rosati
August 01, 2024: SEAM Group, a B2B business products and services company that provides safety, reliability, maintenance, and enterprise asset management services in the hospitality, food processing, and pharmaceutical industries, was acquired by ABB for an undisclosed amount.
Morgan Healthcare Conference in San Francisco, which also saw the announcement of major acquisitions by large players in the pharmaceutical space. The timing of the announcement coincided with the start of the 42nd Annual J.P. By: Knobbe Martens
The Anglo-Swedish company struck an agreement to acquire Fusion Pharmaceuticals, which is developing next-generation radioconjugates that offer an alternative to chemotherapy and radiotherapy.
Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker AstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn (£950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market.
September 2, 2024 – The software mergers and acquisitions (M&A) marketplace has been bustling with activity in the first half of 2024, reflecting the sector’s robust growth and strategic consolidations. billion acquisition of Ansys, a move aimed at bolstering its software capabilities and expanding its market footprint.
Corporate restructuring can be a game-changer for any organization, whether it’s a merger, acquisition, or any other strategic move. Understanding merger vs acquisitionMergers and acquisitions (M&A) are two of the most common forms of corporate restructuring.
Get the Insider Tips You Need to Secure Your Deal - Watch Here rn rn About the Guest(s): rn Patrick O'Connell is an experienced mergers and acquisitions (M&A) advisor with a profound depth of knowledge in buying and selling small businesses valued between one to $20 million. b' E200: Buying or Selling a Small Business?
Move follows fears over jobs and control when private equity firm CD&R entered talks to buy Opella for €16bn The French government is to take a stake in the pharmaceutical company Sanofi’s consumer healthcare division to try to quell a backlash as the US private equity firm Clayton, Dubilier & Rice enters talks to buy the unit for €16bn (£13.3bn). (..)
In recent months, the life sciences industry has seen the reemergence of contingent value rights, or CVRs, in public company acquisitions as a way to bridge a valuation gap between buyers and sellers. Executive Summary This study addresses CVRs, the public M&A analog to the earnout used in private deals, which can be price-driven (e.g.,
The benefits of VR are not limited to language immersion, architecture, interior design, space expedition, biology, chemistry or pharmaceutical practices. They also have developed Daydream Labs where employees can be trained visually and interactively, resulting in a faster learning process [9].
One specific area where these laws are frequently applied is in the context of merger and acquisition transactions. To prevent this from happening, governments often have laws in place that regulate mergers and acquisitions to ensure that they do not create or enhance a monopoly or otherwise harm competition.
Some dealmakers claim the impact of elections on mergers and acquisitions is minimal. billion acquisition of Qualtrics International Inc. Veterinary pharmaceuticals firm Dechra Pharmaceuticals Plc , which EQT agreed to buy for around £4.5 and Permira’s €14 billion ($15.2 billion ($5.7
Washington, DC, (October 20, 2023) – FOCUS Investment Banking (“FOCUS”), a national middle market investment banking firm providing merger, acquisition, divestiture and corporate finance services, announced today that Bearing Distributors, Inc. Schrimsher, President & CEO for Applied. With locations across the U.S.
To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A). Strategic mergers and acquisitions offer a powerful tool to build more resilient supply chains.
In recent months, the life sciences industry has seen the reemergence of contingent value rights, or CVRs, in public company acquisitions as a way to bridge a valuation gap between buyers and sellers. Executive Summary This study addresses CVRs, the public M&A analog to the earnout used in private deals, which can be price-driven (e.g.,
While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. billion; Bristol Myer Squibb’s acquisition of RayzeBio for $4.1 billion; and Roche’s acquisition of Carmot Therapeutics for up to $3.1
Benchmark International is pleased to announce the acquisition of Wicklow-based Paramount Packaging by Mediahuis Ireland, through its Reach Group subsidiary.
The New York Times: Mergers, Acquisitions and Dive
MARCH 6, 2025
Shares of Walgreens Boots Alliance have lost about half their value in the past year, as the chain has faced pressure in its retail and pharmacy businesses.
The healthcare sector is primarily segmented into pharmaceuticals, services, devices, and others. According to Verified Market Research, the global healthcare market will reach $665.37 billion by 2028. By application, the industry is categorized by cardiovascular, oncology, anti-infection, central nervous system, respiratory, and others.
No longer just “acquihires,” today’s innovation-driven acquisition is focused on talent retention. One familiar technique used by sophisticated tech buyers is a holdback structure that subjects a portion of key employees’ merger consideration to revesting. The typical revesting period for these arrangements is 24 to 36 months.
Alexion Pharmaceuticals (Del. This dynamic has increased the number of earnout/milestone disputes and is influencing how earnout provisions are negotiated in acquisition agreements. By July 2018, J&J began considering an acquisition of Auris to have iPlatform as a backup plan for Verb. In both Fortis v.
The New York Times: Mergers, Acquisitions and Dive
DECEMBER 18, 2023
Students and parent volunteers from a school in Washington State said in a lawsuit that they had become sick after being exposed to chemicals known as P.C.B.s. that had dripped from light fixtures.
M&A practitioners have long advised boards of directors that the Delaware courts have never found that the events or circumstances in a particular transaction met the contractual standard of having a material adverse effect (or MAE) as defined in a merger or acquisition agreement. The Merger Agreement. 2018-0300-JTL (Del.
Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business AstraZeneca is buying its first vaccine company in a $1.1bn deal that will expand the vaccine and immune therapy business it set up during the Covid-19 pandemic.
Understanding Freelance Modeling in M&A In the realm of mergers and acquisitions (M&A), freelance modeling emerges as a dynamic and adaptive methodology, offering a departure from traditional approaches. Illustrating this transformative power, consider a merger between a software giant and a cybersecurity startup.
Few companies divest units immediately following an acquisition (unless they are compelled to do so by antitrust regulators), but many companies divest them eventually. In any given year, nearly half of the acquisitions that occur come about because the sellers are divesting a company unit. Sometimes spin-offs precede mergers.
Example : Consider a merger where the primary goal is expanding market share by integrating sales teams. A strategic IMO Lead wouldn’t stop at Day 1 integration; they’d chart a multi-year plan for how the sales team’s merger contributes to larger corporate objectives, like boosting revenue in underperforming regions.
But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.
Ideagen is a leading provider of software solutions to regulated and high-compliance industries, including pharmaceutical, aerospace and defense, and life sciences. The Tritan-Ideagen deal demonstrates the value of strategic acquisitions as a method for entering new markets and expanding globally.
PE firms view these companies as especially appealing since low multiples mean they can use higher debt percentages to fund the acquisitions. Fragmented Markets with Many Add-On Acquisition Opportunities – Private equity firms have been snapping up specialist physician practices in the U.S.
Mergers and acquisitions (M&A) constitute intricate and frequently risky transactions with significant implications for stakeholders. Here are some case studies of successful rationalization in M&A: Pfizer and Wyeth In 2009, Pfizer acquired Wyeth , a global pharmaceutical company, for $68 billion.
For example, while a pharmaceutical company focused solely on shareholder value might prioritize high-margin drugs for rare conditions, a stakeholder-oriented approach might consider affordability and broader societal health needs , as seen with Gilead's approach to its HIV medications.
By melding the proficiencies, assets, and potentials residing within distinct business sectors or entities under a single organizational umbrella, the practice of mergers and acquisitions unveils dormant possibilities, propels inventive evolution, and champions the delivery of unparalleled outcomes. Short on time? Limited on time?
The term “indication” is often used in the biotech/pharmaceutical industry as a term of art, and to describe both developmental as well as commercial milestone events in an acquisition agreement. Throughout the trial, it was evident that the word had various meanings during the negotiations.
While the issue has been intensifying over the past decade, in July the Biden administration proposed new merger guidelines to further protect competition. Additional considerations include how the DOJ and FTC are evaluating transactions including consent decrees, remedy acceptance and merger challenges, Macy said.
The second half of the year witnessed a rebound spurred by several multibillion-dollar deals, including Gilead’s acquisition of Immunomedics for nearly $21 billion and AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39 billion. Life Sciences Enters the SPAC Party, But Will Reverse Merger Suitors Join In?
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content